FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912996634> ?p ?o ?g. }

• W2912996634 endingPage "S176" @default.
• W2912996634 startingPage "S175" @default.
• W2912996634 abstract "BackgroundAdoptive transfer of cytolytic natural killer (NK) cells is limited by the short-term persistence of NK cells and their impaired effector function after infusion. We have previously shown that ex-vivo expansion of NK cells with nicotinamide (NAM) resulted in potent cytotoxicity against multiple tumor cell lines, and robust homing, proliferation and retention in vivo (Blood 2017 130:657). We now report the first-in-human experience of NAM-NK in patients with relapsed/refractory non-Hodgkin lymphoma (NHL) and multiple myeloma (MM).MethodsFollowing donor apheresis, CD3-depleted mononuclear cells were cultured for 2 weeks in the presence of NAM (5mM) and IL-15 (20ng/ml). Patients received lymphodepleting chemotherapy followed by two doses of NAM-NK (Days 0 and 2) and low-dose IL-2. Rituximab or elotuzumab was administered to patients with NHL or MM, respectively, to facilitate tumor targeting and antibody-dependent cellular cytotoxicity.ResultsAs of Oct 2018, 9 patients were enrolled. Of 7 evaluable patients, 5 had refractory NHL (3 follicular and 2 diffuse large cell lymphoma) and 2 had MM. Final NAM-NK product (n=7) contained a median of 98% NK cells. In vitro culture with NAM and IL15 resulted in a 3.8-fold increase in TNC and 40-fold increase in NK cells after 14-16 day culture; expression of homing receptor CD62L increased from 2.9% in apheresis to 21% in final product. CD3 content was kept <0.5% (<5 × 105/kg/dose). NAM-NK was infused in 3 patients at the initial dose (2 × 107/kg) without dose-limiting toxicity (DLT). Transient neutropenia was observed in all 3 with neutropenic fever in 1 patient. The 2nd dose level of NAM-NK (1 × 108/kg) was well-tolerated in 4 patients without DLT or grade 3 or 4 adverse events; no cytokine release syndrome or neurotoxicity were observed. Response assessment at 2 months showed that 3 patients achieved complete metabolic remission (follicular lymphoma 2 patients (Figure 1b), transformed lymphoma 1 patient). One patient with MM had stable disease at 2 months and the second with MM experienced progressive disease. Flow cytometry analysis of peripheral blood showed proliferation of NAM-NK in blood between days 2 and 7 in all tested patients (range 2-55% donor NK cells; Figure 1a). Compared to host NK cells, donor NAM-NK cells in blood demonstrated higher CD16 expression (median 68% vs 82%) and enhanced proliferation (median Ki67 81% vs 99%).ConclusionsNAM-NK cells have been safely administered, were well tolerated and proliferated and persisted in vivo. Promising early evidence of clinical activity was observed in patients with advanced disease. Dose escalation will be followed by an expansion cohort at the MTD. Adoptive transfer of cytolytic natural killer (NK) cells is limited by the short-term persistence of NK cells and their impaired effector function after infusion. We have previously shown that ex-vivo expansion of NK cells with nicotinamide (NAM) resulted in potent cytotoxicity against multiple tumor cell lines, and robust homing, proliferation and retention in vivo (Blood 2017 130:657). We now report the first-in-human experience of NAM-NK in patients with relapsed/refractory non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). Following donor apheresis, CD3-depleted mononuclear cells were cultured for 2 weeks in the presence of NAM (5mM) and IL-15 (20ng/ml). Patients received lymphodepleting chemotherapy followed by two doses of NAM-NK (Days 0 and 2) and low-dose IL-2. Rituximab or elotuzumab was administered to patients with NHL or MM, respectively, to facilitate tumor targeting and antibody-dependent cellular cytotoxicity. As of Oct 2018, 9 patients were enrolled. Of 7 evaluable patients, 5 had refractory NHL (3 follicular and 2 diffuse large cell lymphoma) and 2 had MM. Final NAM-NK product (n=7) contained a median of 98% NK cells. In vitro culture with NAM and IL15 resulted in a 3.8-fold increase in TNC and 40-fold increase in NK cells after 14-16 day culture; expression of homing receptor CD62L increased from 2.9% in apheresis to 21% in final product. CD3 content was kept <0.5% (<5 × 105/kg/dose). NAM-NK was infused in 3 patients at the initial dose (2 × 107/kg) without dose-limiting toxicity (DLT). Transient neutropenia was observed in all 3 with neutropenic fever in 1 patient. The 2nd dose level of NAM-NK (1 × 108/kg) was well-tolerated in 4 patients without DLT or grade 3 or 4 adverse events; no cytokine release syndrome or neurotoxicity were observed. Response assessment at 2 months showed that 3 patients achieved complete metabolic remission (follicular lymphoma 2 patients (Figure 1b), transformed lymphoma 1 patient). One patient with MM had stable disease at 2 months and the second with MM experienced progressive disease. Flow cytometry analysis of peripheral blood showed proliferation of NAM-NK in blood between days 2 and 7 in all tested patients (range 2-55% donor NK cells; Figure 1a). Compared to host NK cells, donor NAM-NK cells in blood demonstrated higher CD16 expression (median 68% vs 82%) and enhanced proliferation (median Ki67 81% vs 99%). NAM-NK cells have been safely administered, were well tolerated and proliferated and persisted in vivo. Promising early evidence of clinical activity was observed in patients with advanced disease. Dose escalation will be followed by an expansion cohort at the MTD." @default.
• W2912996634 created "2019-02-21" @default.
• W2912996634 creator A5008133433 @default.
• W2912996634 creator A5027151969 @default.
• W2912996634 creator A5040860058 @default.
• W2912996634 creator A5061426484 @default.
• W2912996634 creator A5061692821 @default.
• W2912996634 creator A5067489954 @default.
• W2912996634 creator A5070132319 @default.
• W2912996634 creator A5080104357 @default.
• W2912996634 creator A5084167089 @default.
• W2912996634 creator A5084248391 @default.
• W2912996634 date "2019-03-01" @default.
• W2912996634 modified "2023-09-26" @default.
• W2912996634 title "First-in-Human Phase I Study of Nicotinamide-Expanded Related Donor Natural Killer Cells for the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma and Multiple Myeloma" @default.
• W2912996634 doi "https://doi.org/10.1016/j.bbmt.2018.12.317" @default.
• W2912996634 hasPublicationYear "2019" @default.
• W2912996634 type Work @default.
• W2912996634 sameAs 2912996634 @default.
• W2912996634 citedByCount "12" @default.
• W2912996634 countsByYear W29129966342019 @default.
• W2912996634 countsByYear W29129966342021 @default.
• W2912996634 countsByYear W29129966342022 @default.
• W2912996634 crossrefType "journal-article" @default.
• W2912996634 hasAuthorship W2912996634A5008133433 @default.
• W2912996634 hasAuthorship W2912996634A5027151969 @default.
• W2912996634 hasAuthorship W2912996634A5040860058 @default.
• W2912996634 hasAuthorship W2912996634A5061426484 @default.
• W2912996634 hasAuthorship W2912996634A5061692821 @default.
• W2912996634 hasAuthorship W2912996634A5067489954 @default.
• W2912996634 hasAuthorship W2912996634A5070132319 @default.
• W2912996634 hasAuthorship W2912996634A5080104357 @default.
• W2912996634 hasAuthorship W2912996634A5084167089 @default.
• W2912996634 hasAuthorship W2912996634A5084248391 @default.
• W2912996634 hasBestOaLocation W29129966341 @default.
• W2912996634 hasConcept C109316439 @default.
• W2912996634 hasConcept C114684123 @default.
• W2912996634 hasConcept C126322002 @default.
• W2912996634 hasConcept C167672396 @default.
• W2912996634 hasConcept C202751555 @default.
• W2912996634 hasConcept C203014093 @default.
• W2912996634 hasConcept C2777761686 @default.
• W2912996634 hasConcept C2778102761 @default.
• W2912996634 hasConcept C2779338263 @default.
• W2912996634 hasConcept C502942594 @default.
• W2912996634 hasConcept C55493867 @default.
• W2912996634 hasConcept C71924100 @default.
• W2912996634 hasConcept C86803240 @default.
• W2912996634 hasConcept C8891405 @default.
• W2912996634 hasConceptScore W2912996634C109316439 @default.
• W2912996634 hasConceptScore W2912996634C114684123 @default.
• W2912996634 hasConceptScore W2912996634C126322002 @default.
• W2912996634 hasConceptScore W2912996634C167672396 @default.
• W2912996634 hasConceptScore W2912996634C202751555 @default.
• W2912996634 hasConceptScore W2912996634C203014093 @default.
• W2912996634 hasConceptScore W2912996634C2777761686 @default.
• W2912996634 hasConceptScore W2912996634C2778102761 @default.
• W2912996634 hasConceptScore W2912996634C2779338263 @default.
• W2912996634 hasConceptScore W2912996634C502942594 @default.
• W2912996634 hasConceptScore W2912996634C55493867 @default.
• W2912996634 hasConceptScore W2912996634C71924100 @default.
• W2912996634 hasConceptScore W2912996634C86803240 @default.
• W2912996634 hasConceptScore W2912996634C8891405 @default.
• W2912996634 hasIssue "3" @default.
• W2912996634 hasLocation W29129966341 @default.
• W2912996634 hasOpenAccess W2912996634 @default.
• W2912996634 hasPrimaryLocation W29129966341 @default.
• W2912996634 hasRelatedWork W1969995434 @default.
• W2912996634 hasRelatedWork W1983764257 @default.
• W2912996634 hasRelatedWork W1987582507 @default.
• W2912996634 hasRelatedWork W2014715720 @default.
• W2912996634 hasRelatedWork W2017114607 @default.
• W2912996634 hasRelatedWork W2033726015 @default.
• W2912996634 hasRelatedWork W2079447457 @default.
• W2912996634 hasRelatedWork W2397815496 @default.
• W2912996634 hasRelatedWork W2418656659 @default.
• W2912996634 hasRelatedWork W2419386362 @default.
• W2912996634 hasVolume "25" @default.
• W2912996634 isParatext "false" @default.
• W2912996634 isRetracted "false" @default.
• W2912996634 magId "2912996634" @default.
• W2912996634 workType "article" @default.